Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
Conclusions
Although the primary end point was not met, these data suggest a potential treatment effect of cholecalciferol in patients with RRMS already treated with interferon beta-1a and low serum 25OHD concentration. Together with the good safety profile, these data support the exploration of cholecalciferol treatment in such patients with RRMS.
Clinicaltrials.gov identifier
NCT01198132.
Classification of evidence
This study provides Class II evidence that for patients with RRMS and low serum 25OHD, cholecalciferol did not significantly affect ARRs.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Camu, W., Lehert, P., Pierrot-Deseilligny, C., Hautecoeur, P., Besserve, A., Jean Deleglise, A.-S., Payet, M., Thouvenot, E., Souberbielle, J. C. Tags: Clinical trials Randomized controlled (CONSORT agreement), Multiple sclerosis Article Source Type: research
More News: Avonex | Brain | Clinical Trials | Disability | Multiple Sclerosis | Neurology | Rebif | Study | Vitamin D | Vitamin D3 | Vitamins